Swiss Consumer Finance Stock News

SWX:SUNN
SWX:SUNNTelecom

Sunrise Communications Q4 Losses Narrow Yet Still Test Bullish Turnaround Narrative

Sunrise Communications (SWX:SUNN) has wrapped up FY 2025 with Q4 revenue of CHF 788.8 million and a net income loss of CHF 50.1 million, while the trailing twelve months show revenue of CHF 2.98 billion alongside a loss of CHF 112.2 million. The company has seen quarterly revenue move in a tight band between CHF 722.1 million and CHF 788.8 million from Q1 to Q4 2025, with basic EPS ranging from a loss of CHF 0.022 in Q1 to a loss of CHF 0.075 in Q3. This keeps the spotlight squarely on when...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is It Too Late To Consider Novartis (SWX:NOVN) After A 1-Year 35% Rally?

If you are wondering whether Novartis shares still offer value at current levels, this article walks through what the numbers say about the price you are paying versus what you are getting. The stock last closed at $126.48, with returns of 2.2% over 7 days, 10.7% over 30 days, 16.6% year to date, 35.5% over 1 year, 85.7% over 3 years and 104.7% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent headlines around Novartis have...
SWX:AMS
SWX:AMSSemiconductor

Assessing ams-OSRAM (SWX:AMS) Valuation After Open System Protocol Advances Toward ISO Standard Status

ams-OSRAM (SWX:AMS) has attracted fresh attention after its Open System Protocol for automotive lighting progressed toward ISO standard status, positioning the company more firmly within next generation vehicle electronics architectures. See our latest analysis for ams-OSRAM. That progress toward an ISO standard comes shortly after ams-OSRAM reported 2025 results that showed sales of €3,323m with a net loss of €130m, alongside guidance for first quarter 2026 revenues between €710m and €810m...
SWX:COPN
SWX:COPNPharmaceuticals

Assessing Cosmo Pharmaceuticals (SWX:COPN) Valuation After Strong Revenue Update And Share Price Momentum

Cosmo Pharmaceuticals (SWX:COPN) has drawn attention after a strong share price move in recent months, prompting investors to look more closely at how its gastroenterology, dermatology, and healthtech portfolio lines up with current expectations. See our latest analysis for Cosmo Pharmaceuticals. At a share price of CHF122.6, Cosmo Pharmaceuticals has logged a 9.66% 1 month share price return and an 81.90% 3 month share price return. The 1 year total shareholder return of 89.84% suggests...
SWX:BEKN
SWX:BEKNBanks

European Dividend Stocks With Up To 4.8% Yield

As European markets experience volatility amid global concerns over AI disruptions, the pan-European STOXX Europe 600 Index has managed to hit new highs, reflecting resilience in the face of these challenges. In this environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate uncertain times.
SWX:ALSN
SWX:ALSNElectronic

A Look At ALSO Holding (SWX:ALSN) Valuation After Earnings Call And Higher Dividend Announcement

Earnings call and dividend decision draw focus to ALSO Holding (SWX:ALSN) ALSO Holding (SWX:ALSN) is back on investor radars after its 2025 earnings call on 17 February 2026 coincided with the announcement of an annual dividend of CHF 5.30 per share. See our latest analysis for ALSO Holding. The earnings call and dividend announcement came against a weak backdrop, with a 1 day share price return of 31.17% decline and a 1 year total shareholder return of 46.43% decline suggesting momentum has...
SWX:ALC
SWX:ALCMedical Equipment

Is There Now An Opportunity In Alcon (SWX:ALC) After A 23.6% Share Price Drop

This article is designed to help you think clearly about whether Alcon's current share price fairly reflects its potential or if the market might be mispricing it. Alcon closed at $61.90, with a 1.4% gain over the last 7 days, a 3.2% decline over 30 days, a 2.6% decline year to date, and a 23.6% decline over the past year, which may catch the eye of investors reassessing the balance between opportunity and risk. Recent headlines around Alcon have focused on its position within healthcare and...
SWX:BCVN
SWX:BCVNBanks

European Dividend Stocks To Consider In February 2026

As European markets navigate volatility amid AI disruption concerns and digest strong U.S. job data, the pan-European STOXX Europe 600 Index managed to hit a new high, reflecting resilience in the region's economy. In such an environment, dividend stocks can offer investors a measure of stability and income potential, making them an attractive consideration for those looking to balance growth with steady returns.
SWX:ABBN
SWX:ABBNElectrical

Is It Too Late To Consider ABB (SWX:ABBN) After Its Strong Multi‑Year Share Price Run?

If you are wondering whether ABB is still fairly priced after a strong run, this article will walk through what the current share price might be implying about value. ABB's share price closed at CHF 69.80, with returns of 1.7% over 7 days, 13.3% over 30 days, 14.0% year to date, 34.5% over 1 year, 139.7% over 3 years and 215.6% over 5 years. This raises the question of what is already reflected in the price. Recent news around ABB has focused on its position as a global industrial technology...
SWX:NOVN
SWX:NOVNPharmaceuticals

Novartis (SWX:NOVN): Are Renal Bets And Radiopharmaceuticals Quietly Reshaping Its Long-Term Growth Mix?

In early February 2026, Novartis reported final Phase III ALIGN data showing Vanrafia® (atrasentan) slowed kidney function decline in adults with IgA nephropathy, alongside a new long-term Actinium-225 supply agreement from Niowave to support its radioligand therapy portfolio for difficult-to-treat cancers. Together, these updates highlight Novartis’ effort to build depth in both renal disease and radiopharmaceutical oncology, reinforcing the importance of specialized therapies and secure...
SWX:SREN
SWX:SRENInsurance

3 European Dividend Stocks Yielding Up To 5.3%

As European markets navigate volatility, with the STOXX Europe 600 Index recently hitting a new high before settling nearly unchanged, investors are keenly observing economic indicators such as employment growth and GDP expansion in the eurozone. Amidst these dynamics, dividend stocks have gained attention for their potential to provide steady income; qualities like strong cash flow and a history of consistent payouts can make them appealing choices in uncertain market conditions.
SWX:LISN
SWX:LISNFood

Is Lindt’s DubaiStyle Expansion a Clue to Its Everyday Indulgence Strategy for (SWX:LISN) Investors?

In February 2026, Lindt & Sprüngli confirmed the return of its sold‑out DubaiStyle Chocolate to Canadian shelves, reintroducing the 150g bar and adding a new 40g snackable format crafted with smooth milk chocolate, pistachio filling and kadayif pastry. The launch of a portable 40g DubaiStyle bar alongside the original 150g format highlights how Lindt is using premium, culturally inspired recipes to broaden everyday indulgence occasions. We’ll now examine how expanding DubaiStyle into a new...
SWX:BCHN
SWX:BCHNMachinery

Top 3 European Dividend Stocks Offering Up To 5% Yield

As European markets experience volatility amidst global concerns about AI disruption and economic data releases, the pan-European STOXX Europe 600 Index has managed to reach new highs, reflecting a complex investment landscape. In such an environment, dividend stocks can offer a measure of stability and income potential for investors seeking to navigate these uncertain times.
SWX:LONN
SWX:LONNLife Sciences

A Look At Lonza Group’s (SWX:LONN) Valuation After Its Governance And Board Refresh

Board overhaul puts Lonza Group (SWX:LONN) governance in focus Lonza Group (SWX:LONN) has set out a broad board refresh, nominating tech-focused leader Sami Atiya and proposing Claudia Süssmuth-Dyckerhoff as Vice-Chair while several long-serving directors prepare to step down. See our latest analysis for Lonza Group. The board refresh headlines come at a time when Lonza Group’s 1-day share price return of 1.19% and 7-day share price return of 2.21% sit against a 1-year total shareholder...
SWX:ABBN
SWX:ABBNElectrical

Assessing ABB (SWX:ABBN) Valuation After Strong Q4, New Buyback And Electrification Contract Wins

ABB (SWX:ABBN) is back in focus after reporting strong Q4 results, growing orders, and outlining a CHF2.0b share buyback, alongside new contract wins in power and data centre electrification. See our latest analysis for ABB. ABB’s recent Q4 update, the CHF2.0b share buyback and new electrification contracts have arrived alongside a 30 day share price return of 13.6% and a 1 year total shareholder return of 37.6%. Together these developments point to strengthening momentum rather than a short...
SWX:IDIA
SWX:IDIABiotechs

Idorsia (SWX:IDIA) Valuation Check After Lucerastat Phase 3 Agreement With US And European Regulators

Idorsia (SWX:IDIA) is back on investors’ radar after securing regulator alignment in the US and Europe on a streamlined Phase 3 registration program for its Fabry disease candidate, lucerastat. See our latest analysis for Idorsia. The latest lucerastat update lands after a sharp swing in sentiment, with Idorsia’s 1 year total shareholder return very large at about 5.3x. However, the year to date share price return is slightly negative and longer term total shareholder returns over 3 and 5...
SWX:ACLN
SWX:ACLNElectrical

How Accelleron’s Board Succession Overhaul Will Impact Accelleron Industries (SWX:ACLN) Investors

Accelleron Industries has announced a major reshaping of its Board of Directors, proposing Monika Krüsi as Chairwoman and adding Mieke Van de Capelle, while two current directors step down early as part of an accelerated succession plan ahead of the 28 April 2026 AGM. This governance renewal could recalibrate how the company sets priorities in areas such as nomination, compensation, and sustainability oversight, potentially influencing its long-term direction. We’ll now examine how this...
SWX:UBSG
SWX:UBSGCapital Markets

Assessing UBS Group (SWX:UBSG) Valuation After Recent Share Price Volatility

Recent performance and context for UBS Group shares UBS Group (SWX:UBSG) has drawn investor attention after a monthly return of about a 16% decline and a 3‑month gain of roughly 4%, set against a backdrop of mixed shorter-term price moves. See our latest analysis for UBS Group. At a share price of CHF32.10, UBS Group’s recent 1 month share price return of a 16% decline and 7 day share price return of a 5% decline contrast with a 1 year total shareholder return of 9.8% and 5 year total...